June 24, 2009 (FinancialWire) — ImmunoGen, Inc. (NASDAQ: IMGN) has closed its public offering of 5.75 million shares of common stock. The company received net proceeds of around $38.0 million.

Oppenheimer & Co. (NYSE: OPY) acted as the sole book-runner.

Waltham, Massachusetts-based ImmunoGen develops targeted anticancer therapeutics. Compounds utilizing the company’s technology are in clinical testing through ImmunoGen’s own programs and its collaborations with Genentech, sanofi-aventis, Biogen Idec and Biotest.

The company’s most advanced compound, trastuzumab-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.